Press Releases May 28, 2026 07:30 AM

Compass Therapeutics to Participate in Upcoming June Investor Events

Compass Therapeutics announces participation in key June healthcare investor conferences

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
CMPX

Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in June 2026, providing investor presentations and one-on-one meetings to discuss its pipeline of antibody-based therapeutics targeting tumor growth pathways.

Compass Therapeutics to Participate in Upcoming June Investor Events
CMPX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Compass Therapeutics will present at two major healthcare investor conferences in June 2026, increasing visibility within the investor community.
  • The company focuses on oncology drug development, particularly antibody-based therapeutics targeting angiogenesis and immune modulation in tumors.
  • Investor engagement through live presentations and one-on-one meetings aims to update stakeholders on the company's clinical progress and pipeline.
  • Sectors impacted include biotechnology, healthcare, and pharmaceutical industries focused on oncology treatments.

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: https://cmpx.info/jefferies

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: https://cmpx.info/gs

Virtual/Replay availability: Presentations will be archived on Compass’ Events page.

Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

About Compass Therapeutics
Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099 


Risks

  • Clinical-stage pipeline development carries inherent risks of clinical trial failures or delays impacting future commercial viability.
  • Biopharmaceutical regulatory approvals and market competition could affect the success projection of Compass Therapeutics' drug candidates.
  • Broader market volatility and investor sentiment toward biotech stocks could influence the reception of the company's investor presentations and stock price.

More from Press Releases

Flyte (VTAK) Makes Strategic Investment in Volato (SOAR) Jun 8, 2026 AIFA Issues Formal Clarification and Refutation Regarding the Share Acquisition Transaction Involving HyalRoute Communication Group Limited Jun 8, 2026 Green Circle Decarbonize Technology Limited announces Appointment of Mr. Louis Ho Ming Leung as Chief Financial Officer Jun 8, 2026 NCLH Releases Latest Sail & Sustain® Report, Advancing Collective Action Across Environmental and Social Priorities Jun 8, 2026 Shell plc Commences Registered Exchange Offers for Notes Issued in Connection with Prior Private Exchange Offer by Shell Finance US Inc. Jun 8, 2026